An effective integrated program of neonatal screening - as a modern direction of diagnosis of hereditary metabolic diseases in children (literature review)

Authors

DOI:

https://doi.org/10.15574/PP.2024.97.91

Keywords:

an extended neonatal screening, hereditary metabolic diseases, diagnosis, tandem mass spectrometry

Abstract

Today’s challenges contribute to technological progress in various fields of medicine.

The introduction of extended neonatal screening (ENS) for hereditary metabolic diseases (HMDs) became the basis for the revolution of modern diagnostic technologies. Tandem mass spectrometry (TMS) technology has become a real breakthrough in the laboratory diagnosis of a number of HMDs, with the help of which it is possible to quickly determine the concentrations of dozens of different metabolites in a minimum amount of biological material at the same time.

Purpose - to summarize the literature data on the current state, progress, and prospects of extended neonatal screening for hereditary metabolic diseases.

We retrospectively analyzed the data of modern medical literature on ENS programs and investigated the issues of genomics and metabolomics in the practice of screening for HMDs according to scientometric databases: GoogleScholar, NCBI Pubmed, Cochranelibrary. The historical aspects of the formation and application of such a method of modern laboratory diagnosis of HMDs as tandem mass spectrometry are considered separately. Data on the role of genomics and metabolomics in the practice of neonatal screening for inborn errors of metabolism are also presented.

Since the identification of patients by performing ENS provides an opportunity to expand knowledge about the genesis, frequency, genotype/phenotype correlation, and thus preliminary diagnosis and treatment benefit both the health care system and society. Thanks to exome and genome sequencing technologies, detection of a wider range of diseases has become available.

No conflict of interests was declared by the author.

References

Abhyankar S, Goodwin RM, Sontag M, Yusuf C, Ojodu J, McDonald CJ. (2015). An update on the use of health information technology in newborn screening. Seminars in Perinatology. 39(3): 188-193. https://doi.org/10.1053/j.semperi.2015.03.003; PMid:25935354 PMCid:PMC4433800

Arnold GL. (2018, Dec). Inborn errors of metabolism in the 21st century: past to present. Ann Transl Med. 6(24): 467. https://doi.org/10.21037/atm.2018.11.36; PMid:30740398 PMCid:PMC6331363

Beth A. Tarini. The Current Revolution in Newborn Screening. New Technology, Old Controversies. Arch Pediatr AdolescMed. 2007;161(8):767-772. https://doi.org/10.1001/archpedi.161.8.767; PMid:17679658

Boczonadi V, Jennings MJ, Horvath R. (2018). The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett. 592: 703-717. https://doi.org/10.1002/1873-3468.12962; PMid:29288497 PMCid:PMC5873386

Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A et al. (2018). Newborn Screening for Lysosomal Storage Disorders by Tandem Mass Spectrometry in North East Italy. J. Inherit. Metab. Dis. 41: 209-219. https://doi.org/10.1007/s10545-017-0098-3; PMid:29143201

Chepyala D, Kuo H-C, Su K-Y, Liao H-W, Wang S-Y, Chepyala SR et al. (2019). Improved Dried Blood Spot-Based Metabolomics Analysis by a Postcolumn Infused-Internal Standard Assisted Liquid Chromatography-Electrospray Ionization Mass Spectrometry Method. Analytical Chemistry. 91(16): 10702-10712. https://doi.org/10.1021/acs.analchem.9b02050; PMid:31361473

Gaugler S, Rykl J, Wegner I, Däniken T, Fingerhut R, Schlotterbeck G. (2018). Extended and Fully Automated Newborn Screening Method for Mass Spectrometry Detection Int. J. Neonatal Screen. 4(2). URL: www.mdpi.com/journal/neonatalscreening. https://doi.org/10.3390/ijns4010002; PMid:33072928 PMCid:PMC7548895

George RS, Moat SJ. (2016, Mar). Effect of Dried Blood Spot Quality on Newborn Screening Analyte Concentrations and Recommendations for Minimum Acceptance Criteria for Sample Analysis. Clin Chem. 62(3): 466-475. Epub 2015 Dec 8. https://doi.org/10.1373/clinchem.2015.247668; PMid:26647314

Guthrie R, Susi A. (1963). A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 32: 338-43. https://doi.org/10.1542/peds.32.3.338; PMid:14063511

Hannon WH, Therrell BL. (2014). Overview of the History and Applications of Dried Blood Samples. Dried Blood Spots: Applications and Techniques. John Wiley & Sons, Inc., NJ, USA: 1-5. https://doi.org/10.1002/9781118890837.ch1

Hu WT, Kantarci, OH, Merritt JL 2nd et al. (2007). Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch Neurol. 64: 126-128. https://doi.org/10.1001/archneur.64.1.126; PMid:17210820

Kaluarachchi DC, Smith CJ, Klein JM et al. (2018). Polymorphisms in urea cycle enzyme genes are associated with persistent pulmonary hypertension of the newborn. Pediatr Res. 83: 142-147. https://doi.org/10.1038/pr.2017.143; PMid:28609431 PMCid:PMC5811332

Lamari F, Mochel F, Saudubray JM. (2015). An overview of inborn errors of complex lipid biosynthesis and remodelling. J Inherit Metab Dis. 38: 3-18. https://doi.org/10.1007/s10545-014-9764-x; PMid:25238787

McHung DM. (2011). Clinical validation of cutoff target ranges in newborn screening of metabolic disoders by tandem mass spectrometry: a worldwide collaborative project. Anal. Chem. 83(3): 1152-1156. https://doi.org/10.1021/ac102777s; PMid:21192662 PMCid:PMC3442111

Miller DT, Lee K, Gordon AS, Amendola LM, Adelman K, Bale S et al. (2021). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2020 update: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23: 1381-1390. https://doi.org/10.1038/s41436-021-01172-3; PMid:34012068

Remec ZI, Trebusak Podkrajsek K et al. (2021). Next-generation sequencing in newborn screening: a review of current state. Front Genet. 12: 1-11. https://doi.org/10.3389/fgene.2021.662254; PMid:34122514 PMCid:PMC8188483

Scarpa M, Bonham JR, Dionisi-Vici C, Prevot J, Pergent M, Meyts I et al. (2022). Schieleng. Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe The Lancet Regional Health Europe.13: 100311. https://doi.org/10.1016/j.lanepe.2022.100311; PMid:35199083 PMCid:PMC8841274

Tarini BA. (2007). The Current Revolution in Newborn Screening: New Technology, Old Controversies. Arch Pediatr Adolesc Med. 161(8): 767-772. https://doi.org/10.1001/archpedi.161.8.767; PMid:17679658

Watson MS, Lloyd-Puryear MA, Howell RR. (2022). The Progress and Future of US Newborn Screening. Int. J. Neonatal Screen. 8(41): 1-25. https://doi.org/10.3390/ijns8030041; PMid:35892471 PMCid:PMC9326622

Wojcik MH, Gold NB. (2023). Implications of Genomic Newborn Screening for Infant Mortality. Int. J. Neonatal Screen. 9(1): 12. https://doi.org/10.3390/ijns9010012; PMid:36975850 PMCid:PMC10058701

Wojcik MH, Schwartz TS, Thiele KE, Paterson H, Stadelmaier R, Mullen TE et al. (2019). Infant mortality: The contribution of genetic disorders. J. Perinatol. 39: 1611-1619. https://doi.org/10.1038/s41372-019-0451-5; PMid:31395954 PMCid:PMC6879816

Yoon HJ, Kim JH, Jeon TY, Yoo SY, Eo H. (2014, Sep-Oct). Devastating metabolic brain disorders of newborns and young infants. Radiographics. 34(5): 1257-1272. https://doi.org/10.1148/rg.345130095; PMid:25208279

Znamenska TK, Vorobiova OV, Kuznetsov IE, Holota TV, Kryvosheieva VV, Kremezna AV ta insh. (2020). Yakist sukhykh pliam krovi - nevid'iemna skladova shvydkoho vyiavlennia spadkovykh khvorob obminu rechovyn. Neonatolohiia, khirurhiia ta perynatalna medytsyna. 10(4,38): 77-86. https://doi.org/10.24061/2413-4260.X.4.38.2020.9

Published

2024-03-28